0.15
-0.0052(-3.39%)
Currency In USD
| Previous Close | 0.15 |
| Open | 0.14 |
| Day High | 0.15 |
| Day Low | 0.13 |
| 52-Week High | 1.74 |
| 52-Week Low | 0.11 |
| Volume | 48.68M |
| Average Volume | 2.6M |
| Market Cap | 13.45M |
| PE | -0.34 |
| EPS | -0.44 |
| Moving Average 50 Days | 0.17 |
| Moving Average 200 Days | 0.28 |
| Change | -0.01 |
If you invested $1000 in IN8bio, Inc. (INAB) since IPO date, it would be worth $14.82 as of May 31, 2025 at a share price of $0.148. Whereas If you bought $1000 worth of IN8bio, Inc. (INAB) shares 3 years ago, it would be worth $67.06 as of May 31, 2025 at a share price of $0.148.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
IN8bio Presents Preclinical Data Highlighting Potential of INB-619 T Cell Engager (TCE) for Autoimmune Disease at ASGCT 2025
GlobeNewswire Inc.
May 14, 2025 12:00 PM GMT
Powerful B cell Targeting: INB-619 precisely targets and eliminates B cells from lupus patient samples, including harmful IgG1 and IgM antibodies, demonstrating potential as a treatment for autoimmune diseases Innovative Next Generation TCE Platform:
IN8bio Presents Data at ISCT 2025 Demonstrating Proprietary γδ T cell Manufacturing Generates Consistent and Robust Clinical Products
GlobeNewswire Inc.
May 12, 2025 12:00 PM GMT
Company receives ISCT abstract award for the analytical characterization of its manufactured gamma-delta T cell therapies in the INB-100 trial, which has demonstrated durable, relapse-free survival in AML patients. IN8bio’s proprietary gamma-delta T
IN8bio to Present Clinical and Preclinical Data from Gamma-Delta T Cell Platform at Upcoming Scientific Conferences
GlobeNewswire Inc.
Apr 29, 2025 12:00 PM GMT
NEW YORK, April 29, 2025 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies for cancer and autoimmune diseases, today announced that it will present new cli